LigoCyte is a private, clinical-stage biotechnology company focused on developing vaccines and monoclonal antibodies for gastrointestinal and respiratory indications. The Company’s proprietary virus-like particle (VLP) technologies are supporting a broad range of next-generation vaccines to prevent critical infectious diseases.
LigoCyte has funded its product development efforts through a mix of private investment and grants and contracts administered through the National Institutes of Health and the Department of Defense. LigoCyte’s investors include Forward Ventures, JAFCO, Novartis Venture Fund, Fidelity Biosciences, MedImmune Ventures, Athenian Venture Partners and MC Life Sciences Ventures (Mitsubishi International Corporation). GlaxoSmithKline is also a shareholder of the company. |
